EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial

Sebastiaan Dhont iD, Sara Moura Ferreira iD, Xavier Galloo iD, Pieter Martens iD, Evelyne Meekers iD, Katrien Tartaglia, Sébastien Deferm iD, Lieven Herbots iD, Wilfried Mullens iD, Frederik H Verbrugge iD, Jan Verwerft iD, Philippe B Bertrand iD

Circulation · 23.06.2026 · 153 (25) · 1973-1983

DOI: 10.1161/circulationaha.126.080833 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 23.06.2026. Verfasst von Sebastiaan Dhont und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium (S.D., P.M., E.M., S.D., W.M., P.B.B.). Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Stroke Volume, Neprilysin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated. METHODS: This multicenter, randomized, open-label trial with blinded primary endpoint assessment assigned 84 patients with symptomatic HFpEF and at least moderate AFMR within the previous year to sacubitril/valsartan (n=41) or standard-of-care (SOC; n=43). The primary outcome was the 6-month change in the exercise mean pulmonary arterial pressure to cardiac output (mPAP/CO) slope, assessed using cardiopulmonary exercise testing with simultaneous echocardiography (CPETecho). Secondary outcomes included changes in peak oxygen consumption (peak VO 2 ), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, left atrial (LA) volume and function, and AFMR severity in rest and during stress. RESULTS: At 6 months, sacubitril/valsartan significantly improved the mPAP/CO slope compared with SOC (adjusted between-group difference in change, –0.93 mm Hg/L/min; 95% CI, –1.80 to –0.07; P =0.035). This hemodynamic benefit was accompanied by improvements in peak VO 2 (mean change, +0.9 versus –0.6mL/kg/min; P =0.002) and KCCQ (median increase, 10 versus 2 points; P =0.002). Significant reductions in NT-proBNP and LA volume were observed ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart FailureStroke VolumeNeprilysinAminobutyratesAngiotensin Receptor AntagonistsTetrazolesHumansBiphenyl CompoundsFemaleDrug CombinationsMaleValsartanAgedMiddle AgedTreatment OutcomeExercise Test

Stichwörter der Autor:innen

atrial function mitral regurgitationheart failure with preserved ejection fractionsacubitril/valsartan

Substanzen

Biphenyl CompoundsDrug CombinationsNeprilysinValsartansacubitril and valsartan sodium hydrate drug combinationAminobutyratesAngiotensin Receptor AntagonistsTetrazoles

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium (S.D., P.M., E.M., S.D., W.M., P.B.B.).
  • Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (S.D., S.M.F., P.K., E.M., K.T., S.D., L.H., W.M., J.V., P.B.B.).
  • Department of Cardiology, Jessa & Science, Jessa Hospital, Hasselt, Belgium (S.M.F, L.H., J.V.).
  • Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Jette, Belgium (X.G., F.H.V.).
  • Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium (X.G., F.H.V.).

ORCID-Profile: Sebastiaan Dhont, Sara Moura Ferreira, Xavier Galloo, Pieter Martens, Evelyne Meekers, Sébastien Deferm, Lieven Herbots, Wilfried Mullens, Frederik H Verbrugge, Jan Verwerft, Philippe B Bertrand

Förderung

  • FWO

Zitieren

APA

Dhont, S., Moura Ferreira, S., Galloo, X., Martens, P., Meekers, E., Tartaglia, K., Deferm, S., Herbots, L., Mullens, W., Verbrugge, F. H., Verwerft, J., & Bertrand, P. B. (2026). Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation, 153(25), 1973-1983. https://doi.org/10.1161/circulationaha.126.080833

Vancouver

Dhont S, Moura Ferreira S, Galloo X, Martens P, Meekers E, Tartaglia K, et al. Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial. Circulation. 2026;153(25):1973-1983. doi:10.1161/circulationaha.126.080833

BibTeX
@article{Dhont2026,
  author = {Dhont, Sebastiaan and Moura Ferreira, Sara and Galloo, Xavier and Martens, Pieter and Meekers, Evelyne and Tartaglia, Katrien and Deferm, Sébastien and Herbots, Lieven and Mullens, Wilfried and Verbrugge, Frederik H and Verwerft, Jan and Bertrand, Philippe B},
  title = {Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {25},
  pages = {1973--1983},
  doi = {10.1161/circulationaha.126.080833}
}
Kostenlos starten →